Japanese Device Maker Nipro Estimates Further Growth For FY2009
This article was originally published in PharmAsia News
Executive SummaryJapanese medical device maker Nipro's 2008 sales grew by 2.2 percent to ¥175.9 billion. The operating income increased by 8 percent to ¥14.7 billion and net profit increased by 1.7 percent to ¥4.5 billion. In the domestic market, Nipro's dialysis products, injection and intravenous injection products steadily expanded market shares. Its pharmaceutical business also contributed to growth, especially in oral tablets and dialysis medicines. For fiscal year 2009, Nipro estimates further expansion in its pharma business, due largely to growth in the generic drug market and increasing diagnostic procedure combined payment methods. Estimated 2009 sales are ¥180 billion, with ¥6 billion in net product for a 33.5 percent increase. (Click here for more - Japanese language
You may also be interested in...
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.